Enanta Pharmaceuticals, Inc.

ENTA · NASDAQ
Analyze with AI
9/30/2025
9/30/2024
9/30/2023
9/30/2022
Operating Activities
Net Income-$82-$116-$134-$122
Dep. & Amort.$5$2$2$3
Deferred Tax$0$0$0$0
Stock-Based Comp.$19$27$28$27
Change in WC-$2$7$8$7
Other Non-Cash$41$1-$8$0
Operating Cash Flow-$19-$79-$103-$85
Investing Activities
PP&E Inv.-$13-$18-$9-$2
Net Acquisitions$0$0$45-$55
Inv. Purchases-$210-$307-$373-$171
Inv. Sales/Matur.$263$383$329$228
Other Inv. Act.$0$0-$45$55
Investing Cash Flow$40$58-$54$55
Financing Activities
Debt Repay.$0-$27$0$0
Stock Issued$0$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$27-$0$198$20
Financing Cash Flow-$27-$28$198$20
Forex Effect$0$0$0$0
Net Chg. in Cash-$6-$48$41-$10
Supplemental Information
Beg. Cash$41$89$48$58
End Cash$36$41$89$48
Free Cash Flow-$32-$97-$112-$87
Enanta Pharmaceuticals, Inc. (ENTA) Financial Statements & Key Stats | AlphaPilot